CD34
ϩ cells/kg patient weight is recommended, with even more reliably rapid engraftment observed after infusion of higher CD34
ϩ cell doses. [1] [2] [3] [4] CD34 ϩ cells in the peripheral blood are normally present in low numbers. After mobilization with hematopoietic cytokines or chemotherapycontaining regimens, the number of CD34 ϩ cells in the blood increases greatly. However, multiple collections are often required to reach the target dose of CD34 ϩ cells for transplantation, either because of insufficient mobilization, inappropriate timing and/or operation of the collection procedures.
The level of CD34 ϩ cells in the peripheral blood reaches its peak at different times according to the mobilization regimen used. For donors or patients treated with a hematopoietic cytokine such as filgrastim only, the peak value of CD34 ϩ cells in the peripheral blood reliably occurs between the fourth and sixth days, 3, 5, 6 greatly simplifying the management of these donors. However, for patients treated with a chemotherapy-containing regimen, the time to maximal CD34 ϩ cells in the peripheral blood varies greatly. [7] [8] [9] The quantity of CD34 ϩ cells is much higher after treatment with a chemotherapy-containing regimen, but it is also more difficult to determine when peak levels of CD34 ϩ cells are present in the peripheral circulation. Some centers initiate apheresis collections when the white blood cell (WBC) count rebounds to a certain level. However, there is little correlation between the WBC count and the number of CD34 ϩ cells, 7, 10, 11 resulting in inefficient collections and increasing the overall cost of obtaining PBSC for the transplant. Other centers use the quantity of CD34 ϩ cells in the peripheral blood to time initiation of apheresis procedures. We and others have demonstrated a very close correlation between the number of CD34 ϩ cells in the blood and the number of CD34 ϩ cells collected by apheresis. 7, [10] [11] [12] [13] However, the clinical utility of this test for the timing of apheresis is limited by logistical factors. For example, current flow cytometric techniques to measure CD34 ϩ cells are technically difficult and expensive. Also, several hours are usually required to obtain the result, which complicates patient management.
Sysmex has developed a hematology analyzer that identifies a small population of immature myeloid cells in the peripheral blood according to cell size, cell density and differential lysis resistance. [14] [15] [16] The machine parameters for identifying these cells were determined with the use of purified CD34 ϩ cell populations. Enumeration of these cells, designated by Sysmex as hematopoietic progenitor cells (HPC), requires use of a modified lysis solution, but is rapidly and inexpensively accomplished. We studied the HPC count to determine if the quantity of these cells in the peripheral blood of patients and donors who underwent PBSC collections could be correlated with the quantity of CD34 ϩ cells in the apheresis component and could potentially be used to determine the timing of apheresis after administration of chemotherapy-based mobilization regimens.
Materials and methods

Patient and donor population
Patients and donors eligible for this study were referred to the Fred Hutchinson Cancer Research Center (FHCRC) for autologous or allogeneic PBSC transplantation. Patients were referred for autologous PBSC transplantation for treatment of a variety of malignant diseases. Donors eligible for this study were HLA-matched family members donating PBSC for allogeneic transplantation. All patients and donors gave informed consent for the administration of filgrastim with or without preceding chemotherapy and for collection of PBSC. All protocols for PBSC mobilization, collection and transplantation were approved by the Institutional Review Board of the FHCRC.
Mobilization regimens
The choice of mobilization techniques was dictated by the clinical protocols in effect and by the disease status of the patients. For 44 patients, PBSC were mobilized with chemotherapy followed by filgrastim (Amgen, Thousand Oaks, CA, USA), both to reduce the tumor burden and to facilitate PBSC harvesting. Regimens included cyclophosphamide (Cy) 4 g/m 2 i.v. (n ϭ 3); Cy and paclitaxel 250 mg/m 2 i.v. (n ϭ 9); and Cy and etoposide 200 mg/m 2 daily i.v. for 3 days (total dose 600 mg/m 2 ) with (n ϭ 6) or without (n ϭ 9) dexamethasone 10 mg four times daily p.o. for 4 days (total dose 160 mg). 17 For seven patients PBSC were collected after a variety of different chemotherapy regimens specific to the disease being treated. All patients treated with chemotherapy mobilization regimens also received filgrastim 10 g/kg s.c. daily until completion of the collection procedures. In general, apheresis procedures for patients treated with chemotherapy-containing regimens were initiated when the WBC in the peripheral blood exceeded 1 ϫ 10 9 /l after mobilization, although some patients were managed according to peripheral blood CD34 ϩ cell level. For this study, the HPC level in the peripheral blood was not used to time apheresis. For 11 patients who did not need cytoreduction and 11 allogeneic donors, PBSC were mobilized with filgrastim alone at doses of 10-16 g/kg/day s.c. For these patients and donors, apheresis was initiated on the fourth (autologous patients) or fifth (allogeneic donors) day of filgrastim treatment.
Collection of peripheral blood stem cells
A total of 112 PBSC components were collected from 55 patients and 11 normal allogeneic donors using apheresis techniques previously reported. 3, 13 In brief, leukapheresis was performed using a continuous flow blood cell separator (Spectra version 4.7; COBE BCT, Engelwood, CO, USA). Venous access was established either by peripheral vein or central venous catheter. Anticoagulant solution, consisting of heparin 10 U per ml of ACD-A, was infused at a ratio of 1 ml anticoagulant to 30 ml whole blood. A set volume of 12 liters of blood processed per apheresis was used for the adult patients and donors who underwent standard volume apheresis (n ϭ 54 patients and 83 procedures) and up to 6ϫ the patient's total blood volume (TBV) not to exceed 36 liters for patients who underwent large volume apheresis (n ϭ 14 patients and 24 procedures). The blood volume processed was 3ϫ TBV not to exceed 12 liters for pediatric patients (р48 kg) who received standard volume apheresis (n ϭ 4 patients and 5 procedures). Inlet flow rate was maintained at 50-80 ml per minute in the standard volume apheresis procedure, 80-100 ml per minute in the large volume apheresis procedure, and 2 ml/kg per minute not to exceed 80 ml per minute for the pediatric patients. The collection rate was maintained at 1-2 ml per minute. The criterion for adequate PBSC collection was a target number of CD34 ϩ cells of 5 ϫ 10 6 /kg patient weight. Once initiated, leukapheresis was continued daily in an attempt to achieve this goal.
Enumeration of nucleated cells in the peripheral blood and leukapheresis components
WBC counts in the peripheral blood were determined using a Sysmex NE 8000 (Sysmex, Corporation of America, Long Grove, IL, USA). WBC counts in the apheresis components were obtained using a Sysmex E 2500. Cell differentials were manually performed on Wright Giemsa stained specimens and the numbers of mononuclear cells (MNC, defined as lymphocytes and monocytes) were calculated.
Enumeration of HPC
Enumeration of HPC was performed using the Sysmex SE 9500. HPC were identified in the immature information channel (IMI) that uses radio frequency (RF) and direct current (DC) methods to measure cell size and cell density. From the orginal sample, 2.4 l is mixed with a proprietary lytic reagent (STROMATOLYSTER-IM), which lyses mature leukocytes but leaves immature cells intact based on the difference of lipid content between those cells. [14] [15] [16] Using purified CD34 ϩ cells, the lower RF and DC signal were previously identified for the HPC detection area. In the IMI scattergram, HPC are presumed to appear in a distinct area of the blast region. HPC were reported both as absolute number and as a percentage of the WBC in the sample.
Enumeration of CD34
ϩ cells
The quantities of CD34 ϩ cells in the peripheral blood and the leukapheresis component were determined by a standard flow cytometric analysis technique as previously described. 13 A sample of 1 ϫ 10 6 nucleated cells was 
Statistical methods
This is a retrospective study of HPC quantity as a predictor of CD34 ϩ cells collected by apheresis. Patient and donor characteristics, as well as peripheral blood and apheresis components are described using summary statistics such as median values and ranges. Associations between various factors were assessed using Spearman's rank correlation coefficient (). 18 Linear regression models were fitted to the logarithm of the number of CD34 ϩ cells in the apheresis component as a function of the logarithm of CD34 ϩ cells, HPC, WBC and MNC in the peripheral blood. 19 To evaluate the ability of HPC to perform as a diagnostic test for predicting target yields of CD34 ϩ cells of 1 ϫ 10 6 and 2.5 ϫ 10 6 cells/kg, we calculated the sensitivity, specificity and predictive values of HPC, utilizing several different cutoff points for HPC (80, 50, 20, 5 ϫ 10 6 /l). These quantities are defined in Table 1 . Where sufficient data were available, confidence intervals were calculated for these measures using probabilities and standard errors predicted from logis- Table 1 Key measures of accuracy for a diagnostic tool Positive predictive value: Probability of CD34 ϩ cell collection у target for patients with HPC у criterion Negative predictive Probability of CD34 ϩ cell collection Ͻ value:
target for patients with HPC Ͻ criterion Sensitivity:
Probability of HPC у criterion for patients with CD34 ϩ cell collection у target Specificity:
Probability of HPC Ͻ criterion for patients with CD34 ϩ cell collection Ͻ target
Bone Marrow Transplantation tic regression models. Since individual patients may contribute more than one collection to the analysis, standard error estimates used for obtaining confidence intervals were calculated using robust sandwich variance estimates as described previously. 20, 21 Analyses were also conducted using the target value of 5 ϫ 10 6 CD34 ϩ cells per liter of blood processed during apheresis as the definition of an adequate collection (not reported).
Results
Patient and donor population
Patient and donor characteristics are shown in Table 2 . There were 44 patients treated with chemotherapy followed by filgrastim and 22 patients and donors (11 each) who were treated with filgrastim alone.
Cell counts in the peripheral blood and PBSC components
Peripheral blood cell counts and the yield of CD34 ϩ cells for all collections are shown in Table 3 . There were 67 collections after chemotherapy plus filgrastim mobilization regimens and 45 collections after filgrastim only mobilization. The median number of CD34 ϩ cells collected (per kg patient weight) was 2.3 ϫ 10 6 after chemotherapy-containing mobilization and 2.2 ϫ 10 6 for collections after filgrastim alone. The higher median numbers of CD34 ϩ cells (ϫ 10 6 /l) and HPC (ϫ 10 6 /l) in the peripheral blood after chemotherapy-containing mobilization reflects the better mobilization achieved using chemotherapy in combination with cytokines. Similarly, the lower peripheral blood WBC for these patients compared to that for patients and donors treated only with filgrastim reflects the recovery of these patients from marrow-hypoplasia producing chemotherapy regimens. 
The correlation between cell counts in the peripheral blood and the yield of CD34
The relationships between various peripheral blood cell counts at the start of apheresis and CD34 ϩ cell yield (per kg body weight) in the apheresis component are shown in Figure 1 , and the correlation coefficients (categorized by mobilization technique) are listed in Table 4 . For collections after either a chemotherapy-containing mobilization regimen or filgrastim only, the CD34 ϩ cell count was /kg). The number of collections analyzed was 67 from chemotherapy-mobilized patients and 45 from filgrastim only mobilized patients and donors. The number of collections for which CD34 ϩ cell counts from the peripheral blood were available were 28 (after chemotherapy mobilization) and 33 (after filgrastim only mobilization).
highly predictive for the yield of CD34 ϩ cells in the apheresis collection. The HPC level in the peripheral blood had a stronger correlation with CD34 ϩ cell yield than did WBC and MNC counts, but was weaker than the correlation between CD34
ϩ cell count in the peripheral blood and CD34 ϩ cell yield. The correlation coefficients between HPC (ϫ 10 6 /l) and CD34 ϩ cells (ϫ 10 6 /l) in the peripheral blood was 0.55 (n ϭ 28). The correlation coefficients between cell counts in the peripheral blood and CD34 ϩ cell yield per liter of blood processed during the apheresis procedure were found to be very similar to those between cell counts in the peripheral blood and CD34 ϩ cell yields per kg body weight described above (data not shown).
The predictive value of HPC level in the pre-apheresis peripheral blood
The above results suggest that HPC level in the peripheral blood may predict the yield of CD34 ϩ cells collected by apheresis and may be useful in determining when to initiate apheresis procedures after a chemotherapy-based mobilization regimen. We evaluated the HPC level in the peripheral blood as a diagnostic tool for predicting a target yield of CD34 ϩ cells of at least 1 ϫ 10 6 /kg and 2.5 ϫ 10 6 /kg for a defined subset of patients who underwent collection after a chemotherapy-containing regimen and for whom 10-14 liters of blood were processed during the apheresis procedure. We quantified the degree to which higher HPC levels in the peripheral blood were associated with a greater probability of reaching the target yield of CD34 ϩ cells (Table 5) .
For patients with HPC levels у80 ϫ 10 6 /l, all collections reached the target yield of at least 1 ϫ (Table 5) . In other words, one could have more confidence deciding not to carry out apheresis based on a criterion of having an HPC Ͻ80 ϫ 10 6 /l when the goal is to achieve a target of 2.5 ϫ 10 6
CD34
ϩ cells/kg rather than a target of 1 ϫ 10 6 cells/kg. However, this would mean that a higher percentage of aphereses would likely not meet that goal, if the criteria Table 5 The predictive value (95% confidence intervals) of HPC for specific target collections of CD34 ϩ cells among collections in which 10-14 liters of blood were processed were met to carry out the procedure. Because the groups of patients at the extreme HPC levels were small, the confidence intervals are quite wide in these regions and sometimes not estimable. Only one patient had a HPC level below 5 ϫ 10 6 /l on the day of collection (this person failed to reach the target goal of CD34 ϩ cells in the one collection obtained) and the negative predictive value of this cutoff level cannot be determined.
In this study, the percentages of the collections reaching the target yields of 1 ϫ 10 6 and 2.5 ϫ 10 6 CD34 ϩ cells/kg were 80% and 50%, respectively. Therefore, these predictive values of HPC are only applicable to a similar population of patients for which those percentages of collections are expected to reach the target, regardless of HPC levels. However, the sensitivity and specificity of HPC, which are often used to describe the characteristics of a diagnostic test, do not rely on the proportion of the patients who reach the target. Table 6 displays the sensitivity and specificity of HPC as a diagnostic test. The sensitivity decreases and the specificity improves when the cutoff levels of HPC are increased. Figure 2 shows the trade-off in sensitivity and specificity as the cutoff level of HPC is shifted. Among the collections reaching the target yield of 1 ϫ 10 6 CD34 ϩ cells/kg, 100% had a HPC level in the peripheral blood above 5 ϫ 10 6 /l, 89% had a HPC level in the peripheral blood above 20 ϫ 10 6 /l and 71% had a HPC level in the peripheral blood above 50 ϫ 10 6 /l. Among the collections not reaching the target yield of 1 ϫ 10 6 CD34 ϩ cells/kg, 100% had a HPC level in the peripheral blood below 80 ϫ 10 6 /l and 78% had a HPC level in the peripheral blood below 50 ϫ 10 6 /l. Note that because a small number of patients failed to reach the target collection goal of 1 ϫ 10 6 CD34 ϩ cells/kg, the estimates of specificity are accompanied by fairly wide confidence intervals. If the target yield is considered to be 2.5 ϫ 10 6 CD34 ϩ cells/kg, then, in comparison to the target yield of 1 ϫ 10 6 cells/kg, the sensitivity is increased and the specificity is decreased, over the full range of HPC cutoff values. That is, a higher proportion of the successful apheresis collections were Table 6 The sensitivity and specificity of HPC for specific target collections of CD34 ϩ cells amongst collections in which 10-14 liters of blood were processed identified with HPC, while a lower proportion of the unsuccessful apheresis collections were identified with HPC using the higher target CD34 ϩ level.
Discussion
The timing of apheresis is a critical issue for the efficient and cost effective collection of sufficient peripheral blood stem cells for transplantation. A dose of at least 2.5-5.0 ϫ 10 6 /kg CD34 ϩ cells is recommended for reliably rapid hematological recovery, which may take one to more than eight apheresis collections to achieve. [1] [2] [3] [4] For donors and patients treated with hematopoietic cytokines only, apheresis can be performed on the fourth to sixth days of cytokine administration on which the peak value of CD34 ϩ cells in the peripheral blood reliably occurs. 3, 5, 6 However, for patients treated with a chemotherapy-containing regimen, the time to maximal level of CD34 ϩ cells in the peripheral blood varies greatly. [7] [8] [9] Several predictors for CD34 ϩ cells yield have been used by different transplant centers for the timing of apheresis. The quantity of CFU-GM (colonyforming units granulocyte-macrophage) has a close correlation with both CD34 ϩ cell quantity and engraftment, but requires 2 weeks to obtain results. 9, 12, 22 The WBC count, an indicator of bone marrow recovery after chemotherapy administration, has been used to determine when to initiate apheresis after use of a chemotherapy-containing mobilization regimen. We previously published that a WBC count less than 3-5 ϫ 10 9 /l was associated with a very poor yield of CD34 ϩ cells. 13 Furthermore, we and others have demonstrated a poor correlation between WBC and the yield of CD34 ϩ cells. 7, [10] [11] 13 The level of CD34 ϩ cells in the peripheral blood correlates closely with CD34 ϩ cell yield. Several authors have reported that a level of CD34 ϩ cells in the peripheral blood above 10-20 ϫ 10 6 /l was a good threshold at which to initiate apheresis. 7, [11] [12] [13] 22 However, techniques to enumerate CD34 ϩ cells are complex and the reporting of results may take several hours, often resulting in a 1 day delay before apheresis can be started.
Sysmex have developed a technique to measure a population of cells that appears to encompass CD34 ϩ cells. [14] [15] [16] This test was developed using purified CD34 ϩ cells, but unlike flow cytometry-based techniques, requires only 90 s to perform. Detection and enumeration of HPC in the peripheral blood could possibly provide a standard and rapid alternative for predicting the yield of stem cells collected by apheresis. Our data show a correlation between the numbers of HPC and CD34 ϩ cells in the peripheral blood, but at a ratio of about 3 or 4 to 1 indicating that this test also detects a population of CD34 Ϫ cells. Since the HPC population is not equivalent to the population of CD34 ϩ cells it is as expected that the correlation between HPC levels in the peripheral blood and the yield of CD34 ϩ cells is not as high as the correlation between CD34 ϩ cells in the peripheral blood and the yield of CD34 ϩ cells. The types of other cells present in the HPC population were not determined from this study. However, despite the inclusion of CD34 Ϫ cells in the HPC population, we found that the correlation between the number of peripheral blood HPC and the yield of CD34 ϩ cells is better than the correlation between WBC count and the yield of CD34 ϩ cells. The number of HPC predicts the yield of CD34 ϩ cells collected by apheresis and can be used to time the initiation of collection procedure for the patients treated with chemotherapy-based mobilization regimens. By analyzing the predictive values of HPC and sensitivity/specificity of HPC, we found that not only is the correlation of the number of HPC in the peripheral blood with the yield of CD34 ϩ cells better than for WBC levels, but also quantified the degree to which higher HPC levels in the peripheral blood is associated with a greater probability of reaching the target of ϩ cells/kg, the trade-off would be in the opposite direction, with only 67% of collections (above a cutoff level 50 ϫ 10 6 /l HPC) reaching the target and 76% of those below that cutoff not reaching the target. Determining the sensitivity and specificity of HPC enumeration, which is different from the predictive value of HPC, does not rely on the population of the patients who reach the target. Among those collections with CD34 ϩ cell yield above 1 ϫ 10 6 /kg, all had HPC levels above 5 ϫ 10 6 /l, 89% had HPC levels у20 ϫ 10 6 /l and 71% had HPC levels у50 ϫ 10 6 /l. Among collections with CD34 ϩ cell yields below 1 ϫ 10 6 /kg, all had HPC levels below 80 ϫ 10 6 /l and 78% had HPC levels below 50 ϫ 10 6 /l. Among those collections with CD34 ϩ cell yield above 2.5 ϫ 10 6 /kg, all had HPC levels above 5 ϫ 10 6 /l, 91% had HPC levels у20 ϫ 10 6 /l, 82% had HPC levels у50 ϫ 10 6 /l and 77% had HPC levels у80 ϫ 10 6 /l. Among those collections with CD34 ϩ cell yields below 2.5 ϫ 10 6 /kg, 91% had HPC levels below 80 ϫ 10 6 /l and 59% had HPC levels below 50 ϫ 10 6 /l. Taken together, these data suggest that the HPC level of у50 ϫ 10 6 /l may be a valid determinant for deciding when to initiate apheresis procedures after treating a patient with a chemotherapy-based mobilization regimen. Individual collection centers using a higher CD34
ϩ cell target for apheresis may prefer to use a higher HPC cutoff level, such as у80 ϫ 10 6 /l. In conclusion, these data suggest that HPC enumeration using the Sysmex technology can be used to determine when to initiate apheresis after chemotherapy-based mobilization regimens. Patients with high HPC levels in the peripheral blood are also likely to have higher levels of CD34 ϩ cells and require fewer apheresis procedures to achieve the target goal of CD34 ϩ cells for transplantation. HPC enumeration appears to be valuable as a positive predictor of initiating apheresis in that a level above 50 ϫ 10 6 /l is associated with collections meeting our definition of success. However, we cannot be as confident, if the HPC level is below a defined value, that the collection will fail to meet our target goal of CD34 ϩ cells. For this study, we set a low target value of CD34 ϩ cells to be collected in the apheresis procedure as our definition of success. Therefore, a delay in initiating collection when the level of CD34 ϩ cells is presumably increasing may improve subsequent collections and there will be little risk to the patients from a 1 or 2 day delay. The enumeration of HPC may be a valuable tool for laboratories and apheresis centers that have access to this hematology analyzer.
